RDEA3170 AME Study

NCT01910506 ↗

Phase 1 Completed 8 enrolled Ardea Biosciences, Inc.

NaSingle-groupOpen-labelBasic science

Summary

This study will determine the characteristics of absorption, metabolism, and excretion (AME) of RDEA3170 following a single 10 mg dose of RDEA3170 oral solution with 500 microcuries (µCi) of \[14 C\]RDEA3170 in healthy adult male subjects.

Timeline

Start: 2013-08
Primary completion: 2013-09
Completion: 2013-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Verinurad	Small molecule	10 mg	Oral

Indications

No indication recorded.